Crossmark

Prognostic implication of EGFR mutation status and subtype in resected lung adenocarcinoma patients irrespective of therapy

Crossref DOI link: https://doi.org/10.1007/s12094-018-1922-4

Published Online: 2018-07-18

Published Print: 2019-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, R. https://orcid.org/0000-0001-9704-9895
Li, Q.

Lin, S.

Li, W.

Yu, L.

Wang, L.

Dong, X.

Yu, L.

Li, S.

Liu, W.

Li, B.
License Information

Text and Data Mining valid from 2018-07-18
More Information

Article History

Received: 28 May 2018

Accepted: 11 July 2018

First Online: 18 July 2018

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.

: The research is a retrospective study. All the lung cancer patients in this study received radical resection in two hospitals between April 2009 and June 2014. We just investigate the disease-free survival and overall survival between patients with different EGFR mutation status and subtype. So the above statement is not necessary for this research.